INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
19/04/2026
Voltar para busca
Dado oficial do USPTO
STAT-X
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
20/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
20/05/2022
Data de registro
18/07/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
18/07/2023
Última transação
20/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
CN
Examinador
AGREDA, SAMANTHA LEIGH
Localização atual
Historical data usage
Descrição da marca
The mark consists of the stylized wording "STAT-X" where the letter "A" forms a cardiography wave that underlines the remaining letters.
Titulares e representantes
Titulares
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
Representantes
Stacy L. Emhoff Walker & Jocke Co., LPA
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationspharmaceutical preparations for the functional analysis of blood coagulation and fibrinolysis; Pharmaceutical preparations for the quantitative and qualitative detection of substances in human serumplasma and body fluids; Chemico-pharmaceutical preparations for pharmaceutical purposeschemico-pharmaceutical preparations for pharmaceutical purposes for the functional analysis of blood coagulation and fibrinolysis; Chemico-pharmaceutical preparations for pharmaceutical purposes for the quantitative and qualitative detection of substances in human serumplasma and body fluids; Medicated serums used for the functional analysis of blood coagulation and fibrinolysis; Medicated serums used for the quantitative and qualitative detection of analytes in human serumplasma and body fluids; Medicines for serum therapymedicines for serum therapy for functional analysis of blood coagulation and fibrinolysis; Medicines for serum therapy for the quantitative and qualitative detection of substances in human serumplasma and body fluids; Biological preparations for medical purposesbiological preparations for medical purposes for the functional analysis of blood coagulation and fibrinolysis; Biological preparations for medical purposes for the quantitative and qualitative detection of substances in human serumplasma and body fluids; Chemical preparations for pharmaceutical purposeschemical preparations for pharmaceutical purposes for the functional analysis of blood coagulation and fibrinolysis; Chemical preparations for pharmaceutical purposes for the quantitative and qualitative detection of substances in human serumplasma and body fluids; chemical preparations for medical purposeschemical preparations for medical purposes for the functional analysis of blood coagulation and fibrinolysis; chemical preparations for medical purposes for the quantitative and qualitative detection of substances in human serumplasma and body fluids; enzymes for medical purposes; enzyme preparations for medical purposes; Preparations for pharmaceutical purposespreparations for pharmaceutical purposes made of trace elements that are found in the human body for the functional analysis of blood coagulation and fibrinolysis; Preparations for pharmaceutical purposes made of trace elements that are found in the human body for the quantitative and qualitative detection of substances in human serumplasma and body fluids; amino acids for medical purposes; preparations of microorganisms for medical or veterinary use; chemical preparations for the diagnosis of pregnancy; diagnostic preparations for medical purposes; reagent paper for medical purposes; diagnostic biomarker reagents for medical purposes; veterinary preparations for treatment of intestinal bacteria; medicines for veterinary purposes for treatment of intestinal bacteria; biological preparations for veterinary purposes for treatment of intestinal bacteria; chemical preparations for veterinary purposes for treatment of intestinal bacteria; enzymes for veterinary purposes; enzyme preparations for veterinary purposes; diagnostic preparations for veterinary purposes ; reagent paper for veterinary purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
26/08/2025
A7OK
AMENDMENT UNDER SECTION 7 - PROCESSED
06/08/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/06/2025
ES7R
TEAS SECTION 7 REQUEST RECEIVED
16/01/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
19/12/2023
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
19/10/2023
XXCR
GENERIC MADRID TRANSACTION CREATED
19/10/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
18/10/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
18/07/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
18/07/2023
GPNX
NOTIFICATION PROCESSED BY IB
02/05/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/05/2023
PUBO
PUBLISHED FOR OPPOSITION
02/05/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/04/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
12/04/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/04/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
30/03/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/03/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/03/2023
RFNP
REFUSAL PROCESSED BY IB
05/01/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/12/2022
RFRR
REFUSAL PROCESSED BY MPU
08/12/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
28/09/2022
CNRT
NON-FINAL ACTION WRITTEN
27/09/2022
DOCK
ASSIGNED TO EXAMINER
21/09/2022
MAFR
APPLICATION FILING RECEIPT MAILED
19/07/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
15/07/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
14/07/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace STAT-X ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.